Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) EPS (Weighted Average and Diluted) (2021 - 2025)

Amylyx Pharmaceuticals has reported EPS (Weighted Average and Diluted) over the past 5 years, most recently at -$0.28 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.28 for Q4 2025, up 48.15% from a year ago — trailing twelve months through Dec 2025 was -$1.53 (up 65.46% YoY), and the annual figure for FY2025 was -$1.53, up 65.46%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.28 at Amylyx Pharmaceuticals, up from -$0.37 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for AMLX hit a ceiling of $0.31 in Q2 2023 and a floor of -$4.15 in Q4 2021.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.62 (2022), compared with a mean of -$1.03.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): surged 133.33% in 2023 and later tumbled 8850.0% in 2024.
  • Amylyx Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$4.15 in 2021, then soared by 85.06% to -$0.62 in 2022, then skyrocketed by 111.29% to $0.07 in 2023, then tumbled by 871.43% to -$0.54 in 2024, then skyrocketed by 48.15% to -$0.28 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.28 (Q4 2025), -$0.37 (Q3 2025), and -$0.46 (Q2 2025) per Business Quant data.